Freeline Therapeutics Holdings Plc engages in the business of developing and commercializing gene therapies. It also develops gene therapies for bleeding and other debilitating disorders. The company was founded by Markus Hörer and Amit Chunilal Nathwani in 2015 and is headquartered in Stevenage, the United Kingdom.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Freeline Therapeutics Holdings plc - ADR?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Freeline Therapeutics Holdings plc - ADR market cap is $28.24M.
What is the 52-week high for Freeline Therapeutics Holdings plc - ADR?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Freeline Therapeutics Holdings plc - ADR 52 week high is $6.48 as of October 10, 2025.
What is the 52-week low for Freeline Therapeutics Holdings plc - ADR?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Freeline Therapeutics Holdings plc - ADR 52 week low is $6.48 as of October 10, 2025.
What is Freeline Therapeutics Holdings plc - ADR stock price today?
What is the 50-day moving average of Freeline Therapeutics Holdings plc - ADR?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Freeline Therapeutics Holdings plc - ADR 50-day moving average is $6.48.